9,10-seco- Cyclopentanohydrophenanthrene Ring System (e.g., Vitamin D, Etc.) Doai Patents (Class 514/167)
  • Patent number: 11376264
    Abstract: Methods are provided for reducing blood glucose, which utilize an agent that increases the biological activity of a vitamin D receptor (VDR) (e.g., a VDR agonist), in combination with an antagonist of bromodomain-containing protein 9 (BRD9). IN some examples, such methods treat type II diabetes.
    Type: Grant
    Filed: January 8, 2020
    Date of Patent: July 5, 2022
    Assignee: Salk Institute for Biological Studies
    Inventors: Ronald M. Evans, Michael Downes, Zong Wei, Annette Atkins, Ruth T. Yu
  • Patent number: 11304931
    Abstract: Methods of treating a human subject exposed to radiation in space. The methods include the steps of administering to the subject in space a chlorophyll composition sufficient to provide at least about 0.15 ?M of chlorophyll or its metabolites to the subject's bloodstream, and then exposing the subject in space to light having a wavelength of about 620 nm to about 760 nm and an intensity of about 5 W/m2 to about 1000 W/m2 for at least about 5 minutes.
    Type: Grant
    Filed: October 18, 2018
    Date of Patent: April 19, 2022
    Inventor: Adam M. Hasse
  • Patent number: 11305016
    Abstract: The invention provides methods and pharmaceutical compositions for preventing or treating alopecia, such as chemotherapy-induced alopecia (CIA). The pharmaceutical compositions of the invention comprises an effective amount of a vitamin D compound in a formulation that topically delivers the vitamin D compound to the epidermis layer but substantially avoids the dermis layer. In chemotherapy patients, the pharmaceutical compositions of the invention can be administered either before or concurrent with the chemotherapy medication.
    Type: Grant
    Filed: January 16, 2018
    Date of Patent: April 19, 2022
    Assignee: Berg LLC
    Inventors: Joaquin J. Jimenez, Niven Rajin Narain, John Patrick McCook
  • Patent number: 11213551
    Abstract: A substantially water-free ocular treatment composition including about 20% to about 45% beeswax and about 20% to about 45% jojoba oil. The composition can include at least one ingredient selected from the group consisting of shea butter, caprylic/capric triglyceride, phospholipid, sodium hyaluronate, and coconut oil. The composition can be administered to a patient to improve the functionality of the tear film and decrease dry eye symptoms. The composition can be a semi-solid at room temperature and can liquefy when contacted with the skin at body temperature.
    Type: Grant
    Filed: April 5, 2021
    Date of Patent: January 4, 2022
    Assignee: KORB RESEARCH, LLC.
    Inventors: Donald R. Korb, Karl F. Popp, John A. Shipps
  • Patent number: 11179402
    Abstract: A drug delivery system for oral administration of hydrophobic drugs with enhanced and extended absorption and improved pharmacokinetics is provided. In one embodiment, formulations comprising testosterone and testosterone esters, e.g., testosterone palmitate, are disclosed. Methods of treating a hormone deficiency or effecting male contraception with the inventive formulations are also provided.
    Type: Grant
    Filed: November 15, 2017
    Date of Patent: November 23, 2021
    Assignee: Clarus Therapeutics, Inc.
    Inventors: Robert E. Dudley, Panayiotis P. Constantinides
  • Patent number: 11160750
    Abstract: Compositions comprising one or more of the following extracts: an Euterpe oleracea extract comprising cyanidin 3-glycoside and/or cyanidin 3-rutinoside, an Olea europaea extract comprising oleuropein, a Coffea arabica extract, and/or a Tabebuia impetiginosa extract. The compositions further comprise a micronutrient comprising zinc and vitamin D3. Dietary supplements and hair/body care products comprising the compositions. The compositions are useful for non-medicinal treatment of hair loss and/or nourishment and rejuvenation of hair, skin and nails.
    Type: Grant
    Filed: August 2, 2018
    Date of Patent: November 2, 2021
    Assignee: ZIVMAS LLC
    Inventor: Yehoshua Korchia-Maor
  • Patent number: 11109615
    Abstract: The present invention relates to a composition comprising triglycerides, surfactant, self-assembled structures and vitamin A or provitamin A. Further aspects of the invention are a food product, the use of a composition comprising triglycerides, surfactant and self-assembled structures to stabilize vitamin A or provitamin A and a process for preparing a stabilized vitamin A or provitamin A composition.
    Type: Grant
    Filed: February 10, 2016
    Date of Patent: September 7, 2021
    Assignee: Societe des Produits Nestle S.A.
    Inventors: Laurent Sagalowicz, Charlotte Gancel, Cyril Moccand, Isabelle Martiel
  • Patent number: 11103520
    Abstract: The present invention includes a novel method of treating or preventing a disease or disorder associated with low levels of branched N-glycans in a subject in need thereof, the method comprising administering to the subject an effective amount of a compound of the invention. In one embodiment, the subject is further administered at least one additional therapeutic agent.
    Type: Grant
    Filed: April 23, 2015
    Date of Patent: August 31, 2021
    Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Michael Demetriou, James Dennis, Ani Oganesyan
  • Patent number: 11071743
    Abstract: The current invention involves administration to a cancer patient of a combination of therapeutic agents that, as a combination, has more efficacy against brain cancer than any currently available chemotherapeutic agent or chemotherapeutic combination, and that has essentially no toxic effects.
    Type: Grant
    Filed: January 15, 2016
    Date of Patent: July 27, 2021
    Inventor: Gregory M. Fahy
  • Patent number: 11000480
    Abstract: Pediatric and modified release dosage forms of vitamin D compounds, and methods of making and using the dosage forms, are disclosed.
    Type: Grant
    Filed: May 7, 2020
    Date of Patent: May 11, 2021
    Assignee: EIRGEN PHARMA LTD.
    Inventors: Praful Balavant Deshpande, Stephen James Quinlan, Marta Golec, John Gerard O'Brien, James Joseph McDonald, Reem Elamein Elsiddig, Ken O'Shea
  • Patent number: 10792291
    Abstract: This invention discloses uses for levonorgestrel in preparing anti-ovarian cancer products. This invention provides uses for levonorgestrel in the preparation of products to treat ovarian cancer. From carrying out cancer drug repositioning for the FDA- and CFDA-approved drug levonorgestrel, experiments for this invention show, based on screening of non-anti-cancer drugs for various cancer cell lines (tissue types) and mutation sites, that levonorgestrel has a new use as an anti-ovarian cancer medication, thus achieving a new purpose for an old drug.
    Type: Grant
    Filed: June 30, 2015
    Date of Patent: October 6, 2020
    Assignee: SHANGHAI JIAO TONG UNIVERSITY
    Inventors: Yongyong Shi, Zhijian Song
  • Patent number: 10772829
    Abstract: The invention provides aqueous ophthalmic solutions of phentolamine or pharmaceutically acceptable salts thereof, medical kits, and methods for using such ophthalmic solutions to improve visual performance in a patient. Exemplary aqueous ophthalmic solutions include those containing phentolamine mesylate, mannitol, sodium acetate, and water.
    Type: Grant
    Filed: April 30, 2019
    Date of Patent: September 15, 2020
    Assignee: Ocuphire Pharma, Inc.
    Inventor: Alan Meyer
  • Patent number: 10774368
    Abstract: Disclosed is nucleic acid preserving compositions and methods of manufacturing and using the same. Compositions include a carrier, a chaotropic agent, a buffering agent, a chelating agent, a surfactant, an alcohol, an acid, and a mucolytic agent. Compositions as aqueous solutions can include water as a carrier. Preferred embodiments include water, guanidine thiocyanate, Tris, EDTA, SLS, SDA 3C, HCl, and N-acetyl-L-cysteine. Some embodiments include a colored dye as a visual indicator. Methods of manufacturing include combining the components into a mixture, such as an aqueous solution. Methods of use include providing a biological sample that includes nucleic acid and contacting the biological sample with the composition. Kits include the composition disposed in a portion of a biological sample collection apparatus.
    Type: Grant
    Filed: October 31, 2018
    Date of Patent: September 15, 2020
    Assignee: Spectrum Solutions L.L.C.
    Inventor: Federico Carlos Arejola Gaeta
  • Patent number: 10751350
    Abstract: A method of obtaining vitamin D from shiitake includes a) adding ethanol to shiitake powder, followed by reflux extraction, to prepare a shiitake extract; and (b) irradiating ultraviolet (UV) light to the shiitake extract prepared in step (a). When shiitake extracts are obtained and exposed to ultraviolet light under specific conditions, the content of vitamin D2 in the shiitake extracts may be increased.
    Type: Grant
    Filed: October 20, 2015
    Date of Patent: August 25, 2020
    Assignee: JANGHEUNG COUNTY RESEARCH INSTITUTE FOR MUSHROOM INDUSTRY
    Inventors: Kyung-Je Kim, Kyoung Sun Seo, Tae-Young Park, Seong-Woo Jin, Bong-Suk Choi, Jin-Kyeong Kim
  • Patent number: 10736861
    Abstract: Ketogenic compositions including a beta-hydroxybutyrate (BHB) mixed salt are formulated to induce or sustain ketosis in a subject to which the ketogenic compositions are administered. The BHB mixed salt is formulated to provide a biologically balanced set of cationic electrolytes, and is formulated to avoid detrimental health effects associated with imbalanced electrolyte ratios. A ketogenic composition includes BHB salts of at least sodium, potassium, calcium, and magnesium. The BHB salts may also include at least other component such as a BHB compound containing other cations, such as transition metal cations (e.g., zinc or iron), a BHB-amino acid salts, medium chain fatty acid source, vitamin D3, flavorant, or other excipient.
    Type: Grant
    Filed: February 11, 2019
    Date of Patent: August 11, 2020
    Assignee: AXCESS GLOBAL SCIENCES, LLC
    Inventor: Gary Millet
  • Patent number: 10716798
    Abstract: A pharmaceutical composition for tranquilizing cardiomyocytes present in heart muscle in a subject diagnosed with a cardiac overload disease comprises a therapeutically effective amount of a Vitamin D5 compound and a pharmaceutically acceptable excipient. A method for treating or preventing heart failure in a subject diagnosed as having heart failure or being at risk for heart failure, comprises administering to the subject a pharmaceutical composition comprising a therapeutically effective amount of a Vitamin D5 compound and a pharmaceutically acceptable excipient.
    Type: Grant
    Filed: February 21, 2008
    Date of Patent: July 21, 2020
    Assignee: THE REGENTS OF THE UNIVERSITY OF MICHIGAN
    Inventor: Robert U. Simpson
  • Patent number: 10668089
    Abstract: The method of treating elevated blood levels of iPTH by increasing or maintaining blood concentrations of both 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D in a patient by administering, as necessary, both Vitamin D repletion and Vitamin D hormone replacement therapies, is disclosed. The blood concentrations of 25-hydroxyvitamin D are increased to and maintained at or above 30 ng/mL, and blood concentrations of 1,25-dihydroxyvitamin D are increased to or maintained within a patient's normal historical physiological range for 1,25-dihydroxyvitamin D without causing substantially increased risk of hypercalcemia, hyperphosphatemia or over suppression of plasma iPTH in the patient. The blood levels of 25-hydroxyvitamin D are maintained at or above 30 ng/mL between doses of Vitamin D repletion therapies, and the blood levels of 1,25-dihydroxyvitamin D are maintained in the patient's normal historical physiological range between doses of Vitamin D hormone replacement therapies.
    Type: Grant
    Filed: March 12, 2018
    Date of Patent: June 2, 2020
    Assignees: OPKO IRELAND GLOBAL HOLDINGS, LTD., OPKO RENAL, LLC
    Inventors: Charles W. Bishop, Keith H. Crawford, Eric J. Messner, P. Martin Petkovich, Christian F. Helvig
  • Patent number: 10603266
    Abstract: Provided is an eyelash cleaning agent capable of promoting an eyelash elongation effect. The eyelash cleaning agent comprising a cleaning ingredient, and further comprising a vitamin D ingredient, a hair growth ingredient, and a hair loss prevention ingredient, not only reduces a degree of obstruction of the meibomian glands, but also realizes an eyelash elongation effect. Preferably, the vitamin D is vitamin D3, the hair growth ingredient is a ginseng extract, and the hair loss prevention ingredient is kjellmaniella gyrata extract. Additionally, the cleaning ingredient is preferably isostearyl acid or a derivative thereof.
    Type: Grant
    Filed: October 9, 2015
    Date of Patent: March 31, 2020
    Assignee: MEDIPRODUCE, INC.
    Inventor: Eri Kubota
  • Patent number: 10543217
    Abstract: Disclosed is a method of treatment or prevention of frailty in an elderly patient, particularly having an age of 60 or older. The method provides the concomitant parenteral administration of a combination of an anabolic steroid and a vitamin D compound. A preferred combination comprises nandrolone decanoate and cholecalciferol (vitamin D3). The invention, in a further preference, provides a booster therapy to support frail elderly that have undergone hospitalization or surgery to retain independence and regain their regular physical and mental activities.
    Type: Grant
    Filed: August 23, 2010
    Date of Patent: January 28, 2020
    Assignee: Organext Research B.V.
    Inventors: Marjanna Prins, Helenius Jan Kloosterboer
  • Patent number: 10456409
    Abstract: The present invention is directed to compositions and methods for the prevention or treatment of treatment of heterotopic ossification, vascular calcification, or pathologic calcification.
    Type: Grant
    Filed: February 19, 2019
    Date of Patent: October 29, 2019
    Assignee: Nostopharma, LLC
    Inventor: Ekaterina Vert-Wong
  • Patent number: 10391107
    Abstract: The present invention includes a method of suppressing systemic immune response in a subject, the method comprising topically administering a pharmaceutically effective amount of a vitamin D analog to a subject in need thereof. The present invention further includes a method of treating an autoimmune disease in a subject, the method comprising topically administering a pharmaceutically effective amount of a vitamin D analog to a subject in need thereof.
    Type: Grant
    Filed: March 16, 2016
    Date of Patent: August 27, 2019
    Assignee: The Trustees of the University of Pennsylvania
    Inventor: Taku Kambayashi
  • Patent number: 10278918
    Abstract: The invention provides aqueous ophthalmic solutions of phentolamine or pharmaceutically acceptable salts thereof, medical kits, and methods for using such ophthalmic solutions to improve visual performance in a patient. Exemplary aqueous ophthalmic solutions include those containing phentolamine mesylate, mannitol, sodium acetate, and water.
    Type: Grant
    Filed: October 13, 2017
    Date of Patent: May 7, 2019
    Assignee: Ocuphire Pharma, Inc.
    Inventor: Alan Meyer
  • Patent number: 10245250
    Abstract: Methods for improving the visual processing of a healthy infant by administering a composition comprising RRR-alpha-tocopherol to the infant are disclosed. Methods for improving the visual acuity of a healthy infant by administering a composition comprising RRR-alpha-tocopherol to the infant are also disclosed. Methods for improving the development of the visual processing, visual acuity, or both, of an infant by administering a composition comprising RRR-alpha-tocopherol to the infant are also disclosed.
    Type: Grant
    Filed: May 11, 2018
    Date of Patent: April 2, 2019
    Assignee: ABBOTT LABORATORIES
    Inventors: Matthew Kuchan, Chron-Si Lai, Jacqueline Boff
  • Patent number: 10226511
    Abstract: The present invention generally relates to compositions and methods for topical or transdermal delivery, including treatment and prevention of learning and memory disorders, and enhancement of learning or memory. In some cases, the composition may include nitric oxide and/or peptides such as thyrotropin-releasing hormone (TRH) and/or GnRH (gonadotropin-releasing hormone). The nitric oxide and/or peptide may be present within a first phase comprising a lecithin, such as phosphatidylcholine. In certain embodiments, the lecithin is present in liposomes, micelles, or other structures containing nitric oxide and/or peptide. The composition can take the form of a gel, a cream, a lotion, an ointment, a solution, a solid “stick,” etc., that can be rubbed or sprayed onto the skin. Other aspects of the present invention are generally directed to methods of making or using such compositions, methods of promoting such compositions, kits including such compositions, or the like.
    Type: Grant
    Filed: August 2, 2017
    Date of Patent: March 12, 2019
    Assignee: Transdermal Biotechnology, Inc.
    Inventor: Nicholas V. Perricone
  • Patent number: 10213439
    Abstract: The present invention is a compound comprising an anti-inflammatory drug component consisting preferably of at least one of an NSAID portion and a cannabis portion and at least one of a progestin component and a progesterone component. The compound may take for instance the form of a pill or pellet (for oral internal use or for subdermal implantation), an injectable solution, or a suppository. The compound is intended for use in treating subjects having or being at increased risk—especially genetically determined risk—of developing endometriosis. The compound may also be used for treating other disorders or as a contraceptive.
    Type: Grant
    Filed: October 5, 2015
    Date of Patent: February 26, 2019
    Assignee: Predictive Therapeutics, LLC
    Inventor: Bradley C. Robinson
  • Patent number: 10188603
    Abstract: The present invention generally relates to compositions and methods for topical or transdermal delivery, and treatment of sexual dysfunction. The compositions can be used in a variety of applications, including treating erectile dysfunction or sexual dysfunction. In some cases, the composition may include nitric oxide and/or peptides. The nitric oxide and/or peptide may be present within a first phase comprising a lecithin, such as phosphatidylcholine. In certain embodiments, the lecithin is present in liposomes, micelles, or other vesicles containing nitric oxide, peptides, or both. The composition can take the form of a gel, a cream, a lotion, an ointment, a solution, a solid “stick,” etc., that can be rubbed or sprayed onto the skin, e.g., onto the penis, vulva, or other suitable portion of the skin. The composition can also be applied to a mucosal surface in some instances.
    Type: Grant
    Filed: June 9, 2017
    Date of Patent: January 29, 2019
    Assignee: Transdermal Biotechnology, Inc.
    Inventor: Nicholas V. Perricone
  • Patent number: 10149831
    Abstract: The present invention relates to a pharmaceutical; composition comprising an effective amount of vitamin C, zinc, vitamin A, vitamin D3, vitamin B6, garlic and Echinacea to treat bacterial and/or viral infections, and a method for treating bacterial and/or viral infections by orally administering the composition to a patient effective to reduce symptoms of bacterial and/or viral infections such a cold and influenza.
    Type: Grant
    Filed: February 9, 2018
    Date of Patent: December 11, 2018
    Inventor: Edward Wick
  • Patent number: 10122590
    Abstract: A network tracing engine is configured to trace and depict a topology (i.e., a network configuration) of a network using, for example, a network diagram. The network tracing engine preferably queries/telnets to interfaces of routers associated with one or more source-to-destination paths in a network concurrently and independently to ensure proper configuration of the routers and/or to generate a true depiction of a routing configuration without redundantly querying routers.
    Type: Grant
    Filed: June 30, 2017
    Date of Patent: November 6, 2018
    Assignee: AT&T INTELLECTUAL PROPERTY I, L.P.
    Inventor: Raymond Washburn
  • Patent number: 10111896
    Abstract: The present invention concerns a combination of (i) a DNA methylation inhibitor, and (ii) a Vitamin D receptor agonist, for simultaneous or sequential use in the treatment of a drug resistant cancer and/or in prevention of tumor relapse in a patient suffering from cancer. The present invention also relates to a combination of (i) a DNA methylation inhibitor, and (ii) a Vitamin D receptor agonist, for increasing, restoring or enhancing sensitivity of a patient suffering from cancer to a chemotherapeutic drug in a patient suffering from cancer.
    Type: Grant
    Filed: June 19, 2015
    Date of Patent: October 30, 2018
    Assignees: Institut National de la Sante et de la Recherche Medicale (INSERM), Centre National de la Recherche Scientifique (C.N.R.S.), Universite Paris Descartes, Foundation Imagine, Universite Paris Diderot—Paris 7, Universite Paris—Sud, Assistance Publique-Hopitaux de Paris (APHP)
    Inventors: Ivan Cruz-Moura, Olivier Hermine, Etienne Paubelle, Michael Dussiot, Thiago Trovati Maciel, Florence Zylbersztejn
  • Patent number: 10098897
    Abstract: This document provides methods and materials for reducing development of stenosis of arteriovenous fistulas. For example, methods and materials for reducing IEX-1 polypeptide expression or activity within a mammal (e.g., a human) to reduce venous neointimal hyperplasia and/or the development of stenosis of arteriovenous fistulas are provided.
    Type: Grant
    Filed: July 17, 2015
    Date of Patent: October 16, 2018
    Assignee: Mayo Foundation for Medical Education and Research
    Inventors: Sanjay Misra, Rajiv Kumar
  • Patent number: 10071958
    Abstract: According to the present invention, it becomes possible to perform a process for converting into an ?-substituted cysteine represented by general formula (1) or a salt thereof at low cost and on an industrial scale by employing a process that is routed through a compound represented by general formula (3) to a compound represented by general formula (6). Particularly, by employing a process that is routed through a compound represented by general formula (7-2), it becomes possible to detach a tert-butyl protection group in a simple manner and to produce the compound represented by general formula (1) with high purity. Furthermore, by employing a process that is routed through tert-butylthiomethanol or a process that is routed through a compound represented by general formula (9), it becomes possible to produce a compound represented by general formula (2) without generating bischloromethylether that is an oncogenic substance.
    Type: Grant
    Filed: May 1, 2014
    Date of Patent: September 11, 2018
    Assignee: API Corporation
    Inventors: Yuuki Asuma, Hisatoshi Uehara, Tomoko Maeda, Yasuyo Saito, Ryoma Miyake, Hiroshi Kawabata
  • Patent number: 10046000
    Abstract: Disclosed are methods of administering 2-methylene-19-nor-(20S)-1?,25-dihydroxyvitamin D3 to treat and/or prevent secondary hyperparathyroidism and/or its accompanying symptoms in a subject having or at risk for developing secondary hyperparathyroidism.
    Type: Grant
    Filed: May 24, 2017
    Date of Patent: August 14, 2018
    Assignee: Wisconsin Alumni Research Foundation
    Inventors: Hector F. DeLuca, Lori A. Plum, Julia B. Zella, Margaret Clagett-Dame
  • Patent number: 10034896
    Abstract: The present invention generally relates to compositions and methods for treatment of subjects having or at risk of osteoporosis or other conditions. In some cases, the composition may include nitric oxide. The nitric oxide may be present within a first phase comprising a lecithin, such as phosphatidylcholine. In certain embodiments, the lecithin is present in liposomes, micelles, or other vesicles containing nitric oxide. The composition can take the form of a gel, a cream, a lotion, an ointment, a solution, a solid “stick,” etc., that can be rubbed or sprayed onto a suitable portion of the skin. Other aspects of the present invention are generally directed to methods of making or using such compositions, methods of promoting such compositions, kits including such compositions, or the like.
    Type: Grant
    Filed: September 29, 2016
    Date of Patent: July 31, 2018
    Assignee: Transdermal Biotechnology, Inc.
    Inventor: Nicholas V. Perricone
  • Patent number: 10034897
    Abstract: The present invention generally relates to compositions and methods for treatment of subjects in need of muscle growth or repair. In some cases, the composition may include nitric oxide. The nitric oxide may be present within a first phase comprising a lecithin, such as phosphatidylcholine. In certain embodiments, the lecithin is present in liposomes, micelles, or other vesicles containing nitric oxide. The composition can take the form of a gel, a cream, a lotion, an ointment, a solution, a solid “stick,” etc., that can be rubbed or sprayed onto the skin, e.g., onto a location where muscle growth is desired, or on another suitable portion of the skin. Other aspects of the present invention are generally directed to methods of making or using such compositions, methods of promoting such compositions, kits including such compositions, or the like.
    Type: Grant
    Filed: September 30, 2016
    Date of Patent: July 31, 2018
    Assignee: Transdermal Biotechnology, Inc.
    Inventor: Nicholas V. Perricone
  • Patent number: 10034898
    Abstract: The present invention generally relates to compositions and methods for treatment of various inflammatory diseases, such as inflammatory dermatoses and other conditions, e.g., using nitric oxide. Examples of such dermatoses include psoriasis, atopic dermatitis, and contact dermatitis. The nitric oxide may be present within a first phase comprising a lecithin, such as phosphatidylcholine. In certain embodiments, the lecithin is present in liposomes, micelles, or other vesicles containing nitric oxide. The composition can take the form of a gel, a cream, a lotion, an ointment, a solution, a solid “stick,” etc., that can be rubbed or sprayed onto the skin, e.g., onto an inflammation site, or other suitable portion of the skin. Other aspects of the present invention are generally directed to methods of making or using such compositions, methods of promoting such compositions, kits including such compositions, or the like.
    Type: Grant
    Filed: September 30, 2016
    Date of Patent: July 31, 2018
    Assignee: Transdermal Biotechnology, Inc.
    Inventor: Nicholas V. Perricone
  • Patent number: 9993457
    Abstract: Methods for improving the visual processing of a healthy infant by administering a composition comprising RRR-alpha-tocopherol and a carotenoid to the infant are disclosed. Methods for improving the visual acuity of a healthy infant by administering a composition comprising RRR-alpha-tocopherol and a carotenoid to the infant are also disclosed. Methods for improving the visual processing of a healthy infant by administering a composition comprising RRR-alpha-tocopherol to the infant are disclosed. Methods for improving the visual acuity of a healthy infant by administering a composition comprising RRR-alpha-tocopherol to the infant are also disclosed. Methods for improving the development of the visual processing, visual acuity, or both, of an infant by administering a composition comprising RRR-alpha-tocopherol to the infant are also disclosed.
    Type: Grant
    Filed: November 25, 2015
    Date of Patent: June 12, 2018
    Assignee: Abbott Laboratories
    Inventors: Matthew Kuchan, Chron-Si Lai, Jacqueline Boff
  • Patent number: 9968635
    Abstract: The present invention generally relates to compositions and methods for treatment of skin and/or other soft tissues that are infected with bacteria such as Staphylococcus aureus, and/or other infectious organisms. In some cases, the composition may include nitric oxide. The nitric oxide may be present within a first phase comprising a lecithin, such as phosphatidylcholine. In certain embodiments, the lecithin is present in liposomes, micelles, or other vesicles containing nitric oxide. The composition can take the form of a gel, a cream, a lotion, an ointment, a solution, a solid “stick,” etc., that can be rubbed or sprayed onto the skin, e.g., onto a site of infection, or on another suitable portion of the skin. Other aspects of the present invention are generally directed to methods of making or using such compositions, methods of promoting such compositions, kits including such compositions, or the like.
    Type: Grant
    Filed: September 30, 2016
    Date of Patent: May 15, 2018
    Assignee: Transdermal Biotechnology, Inc.
    Inventor: Nicholas V. Perricone
  • Patent number: 9968634
    Abstract: The present invention generally relates to compositions and methods for treatment of subjects having or at risk of neuropathic pain or other conditions. In some cases, the composition may include nitric oxide. The nitric oxide may be present within a first phase comprising a lecithin, such as phosphatidylcholine. In certain embodiments, the lecithin is present in liposomes, micelles, or other vesicles containing nitric oxide. The composition can take the form of a gel, a cream, a lotion, an ointment, a solution, a solid “stick,” etc., that can be rubbed or sprayed onto the skin, e.g., onto a location with neuropathic pain, or on another suitable portion of the skin. Other aspects of the present invention are generally directed to methods of making or using such compositions, methods of promoting such compositions, kits including such compositions, or the like.
    Type: Grant
    Filed: September 30, 2016
    Date of Patent: May 15, 2018
    Assignee: Transdermal Biotechnology, Inc.
    Inventor: Nicholas V. Perricone
  • Patent number: 9950004
    Abstract: The present invention generally relates to compositions and methods for transdermal drug delivery, including treatment and prevention of learning and memory disorders, and enhancement of learning or memory. In some cases, the composition may include nitric oxide. The nitric oxide may be present within a first phase comprising a lecithin, such as phosphatidylcholine. In certain embodiments, the lecithin is present in liposomes, micelles, or other vesicles containing nitric oxide. The composition can take the form of a gel, a cream, a lotion, an ointment, a solution, a solid “stick,” etc., that can be rubbed or sprayed onto the skin. Other aspects of the present invention are generally directed to methods of making or using such compositions, methods of promoting such compositions, kits including such compositions, or the like.
    Type: Grant
    Filed: September 30, 2016
    Date of Patent: April 24, 2018
    Assignee: Transdermal Biotechnology, Inc.
    Inventor: Nicholas V. Perricone
  • Patent number: 9943530
    Abstract: Methods and compositions for treating 25-hydroxyvitamin D insufficiency and deficiency in a patient are described herein. The method includes orally administering to the patient a delayed, sustained release formulation including a first ingredient selected from the group consisting of 25-hydroxyvitamin D2, 25-hydroxyvitamin D3, or a combination of 25-hydroxyvitamin D2 and 25-hydroxyvitamin D3, or it includes gradually administering to the patient a sterile intravenous formulation including a first ingredient selected from the group consisting of 25-hydroxyvitamin D2, 25-hydroxyvitamin D3, or a combination of 25-hydroxyvitamin D2 and 25-hydroxyvitamin D3.
    Type: Grant
    Filed: November 19, 2014
    Date of Patent: April 17, 2018
    Assignee: OPKO RENAL, LLC
    Inventors: Charles W. Bishop, Keith H. Crawford, Eric J. Messner
  • Patent number: 9937162
    Abstract: Methods are provided of treating and preventing stroke diseases, such as cerebral cavernous malformation, by the administration of tempol and/or cholecalciferol.
    Type: Grant
    Filed: April 8, 2016
    Date of Patent: April 10, 2018
    Assignee: THE UNIVERSITY OF UTAH RESEARCH FOUNDATION
    Inventors: Christopher C. Gibson, Dean Y. Li
  • Patent number: 9913852
    Abstract: The method of treating elevated blood levels of iPTH by increasing or maintaining blood concentrations of both 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D in a patient by administering, as necessary, both Vitamin D repletion and Vitamin D hormone replacement therapies, is disclosed. The blood concentrations of 25-hydroxyvitamin D are increased to and maintained at or above 30 ng/mL, and blood concentrations of 1,25-dihydroxyvitamin D are increased to or maintained within a patient's normal historical physiological range for 1,25-dihydroxyvitamin D without causing substantially increased risk of hypercalcemia, hyperphosphatemia or over suppression of plasma iPTH in the patient. The blood levels of 25-hydroxyvitamin D are maintained at or above 30 ng/mL between doses of Vitamin D repletion therapies, and the blood levels of 1,25-dihydroxyvitamin D are maintained in the patient's normal historical physiological range between doses of Vitamin D hormone replacement therapies.
    Type: Grant
    Filed: July 27, 2016
    Date of Patent: March 13, 2018
    Assignees: OPKO IRELAND GLOBAL HODLINGS, LTD., OPKO RENAL, LLC
    Inventors: Charles W. Bishop, Keith H. Crawford, Eric J. Messner, P. Martin Petkovich, Christian F. Helvig
  • Patent number: 9901576
    Abstract: Stable phenobarbital sodium solutions for injection that do not generate impurities during extended storage. These solutions include phenobarbital sodium in an amount of 15 to 200 mg/mL; a C1-C4 alcohol such as ethanol in an amount of 105 to 160 mg/mL; and a glycol such as propylene glycol in an amount of between 620 and 830 mg/mL and have a pH of between 9 and 12 which is adjusted to that range by adding acid or base, as required. No more than 50 mg/mL water is present including any water introduced by the acid or base. The solutions contain no more than 0.8% of phenyl ethyl acetyl urea impurity as well as no detectable amount of phenyl butyric acid after two years storage at room temperature.
    Type: Grant
    Filed: November 18, 2016
    Date of Patent: February 27, 2018
    Assignee: West-Ward Pharmaceuticals International Limited
    Inventors: Michael G. Parker, Scott S. Wilson, Yasmeen Chahal, Kelly W. Hovius, David E. McAnany
  • Patent number: 9877975
    Abstract: The present invention aims to provide an agent for treating meibomian gland dysfunction. The present invention provides an agent for treating meibomian gland dysfunction, which contains activated vitamin D3 or a derivative thereof as an active ingredient.
    Type: Grant
    Filed: June 27, 2014
    Date of Patent: January 30, 2018
    Assignee: Keio University
    Inventors: Kazuo Tsubota, Reiko Arita, Masataka Ito
  • Patent number: 9861644
    Abstract: A stabilized formulation for controlled release of a vitamin D compound is disclosed. The formulation comprises one or both of 25-hydroxyvitamin D2 and 25-hydroxyvitamin D3 and a cellulosic compound. The stabilized formulations exhibit a stable dissolution profile following exposure to storage conditions and demonstrate improved pharmacokinetic parameters compared to unstabilized formulations.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: January 9, 2018
    Assignee: OPKO IRELAND GLOBAL HOLDINGS, LTD.
    Inventors: Jay A. White, Samir P. Tabash, Sammy A. Agudoawu, Joel Z. Melnick
  • Patent number: 9844565
    Abstract: The present invention generally relates to compositions and methods for treatment of subjects having or at risk of acne or other conditions. In some cases, the composition may include nitric oxide. The nitric oxide may be present within a first phase comprising a lecithin, such as phosphatidylcholine. In certain embodiments, the lecithin is present in liposomes, micelles, or other vesicles containing nitric oxide. The composition can take the form of a gel, a cream, a lotion, an ointment, a solution, a solid “stick,” etc., that can be rubbed or sprayed onto the skin, e.g., onto a location with acne, or on another suitable portion of the skin. Other aspects of the present invention are generally directed to methods of making or using such compositions, methods of promoting such compositions, kits including such compositions, or the like.
    Type: Grant
    Filed: September 30, 2016
    Date of Patent: December 19, 2017
    Assignee: Transdermal Biotechnology, Inc.
    Inventor: Nicholas V. Perricone
  • Patent number: 9814736
    Abstract: Disclosed are methods of administering 2-methylene-19-nor-(20S)-1?,25-dihydroxyvitamin D3 to treat and/or prevent secondary hyperparathyroidism and/or its accompanying symptoms in a subject having or at risk for developing secondary hyperparathyroidism, including a subject previously administered a calcimimetic.
    Type: Grant
    Filed: October 31, 2016
    Date of Patent: November 14, 2017
    Assignee: Wisconsin Alumni Research Foundation
    Inventors: Hector F. DeLuca, Lori A. Plum, Margaret Clagett-Dame
  • Patent number: 9775903
    Abstract: This present disclosure is directed to novel prodrugs of activated vitamin D3 compounds. The prodrugs can be designed to have one or more beneficial properties, such as selective inhibition of the enzyme CYP24, low calcemic activity, and anti-proliferative activity. Specifically, these prodrugs are 1-deoxy prohormones of active Vitamin D analogs, e.g. analogs of calcitriol. This disclosure is also directed to pharmaceutical and diagnostic compositions containing the prodrugs of the invention, and to their medical use, particularly as prodrugs in the treatment and/or prevention of diseases.
    Type: Grant
    Filed: January 13, 2011
    Date of Patent: October 3, 2017
    Assignees: JOHNS HOPKINS UNIVERSITY, OPKO IRELAND GLOBAL HOLDINGS, LTD.
    Inventors: Gary H. Posner, Lindsey C. Hess, Alvin S. Kalinda, Rachel D. Slack, Uttam Saha, P. Martin Petkovich
  • Patent number: 9757392
    Abstract: The present invention discloses a novel use of a lanostane having the following formula (I) in enhancing uptake of nutrients: wherein R1 is either H or CH3; R2 is OCOCH3, ?O or OH; R3 is H or OH; R4 is —C(?CH2)—C(CH3)2Ra, in which Ra is H or OH, or —CH?C(CH3)—Rb, in which Rb is CH3 or CH2OH; R5 is H or OH; and R6 is CH3 or CH2OH.
    Type: Grant
    Filed: March 31, 2009
    Date of Patent: September 12, 2017
    Assignee: Sinphar Pharmaceutical Co., Ltd.
    Inventors: Hang-Ching Lin, Tsu-Chung Chang, Wen-Liang Chang, Yi-Yang Song
  • Patent number: 9722880
    Abstract: The preferred embodiments of the present invention are directed to a network tracing engine for tracing and depicting a topology (i.e. a network configuration) of a network using, for example, a network diagram. The network tracing engine preferably queries/telnets to interfaces of routers associated with one or more source-to-destination paths in a network concurrently and independently to ensure proper configuration of the routers and/or to generate a true depiction of a routing configuration without redundantly querying routers.
    Type: Grant
    Filed: April 12, 2016
    Date of Patent: August 1, 2017
    Assignee: AT&T INTELLECTUAL PROPERTY I, L.P.
    Inventor: Raymond Washburn